Search Results - "SCHROEDER, Georgene"

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases by Mesa, Ruben A., Li, Chin-Yang, Ketterling, Rhett P., Schroeder, Georgene S., Knudson, Ryan A., Tefferi, Ayalew

“…Among 2333 consecutive patients with myelofibrosis with myeloid metaplasia (MMM) seen at our institution, 91 fulfilled the World Health Organization (WHO)…”
Get full text

Bone Marrow Angiogenesis in 400 Patients with Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, and Primary Amyloidosis by RAJKUMAR, S. Vincent, MESA, Ruben A, KYLE, Robert A, RUSSELL, Stephen J, GREIPP, Philip R, FONSECA, Rafael, SCHROEDER, Georgene, PLEVAK, Matthew F, DISPENZIERI, Angela, LACY, Martha Q, LUST, John A, WITZIG, Thomas E, GERTZ, Morie A

“…Purpose: To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal…”
Get full text

Oral glutamine reduces the duration and severity of stomatitis after cytotoxic cancer chemotherapy by Anderson, Peter M., Schroeder, Georgene, Skubitz, Keith M.

“…BACKGROUND Mouth sores and/or difficulty swallowing are common and painful consequences of cytotoxic chemotherapy for cancer. In previous studies oral…”
Get full text

A phase II trial of pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone), a novel anti‐fibrosing agent, in myelofibrosis with myeloid metaplasia by Mesa, Ruben A., Tefferi, Ayalew, Elliott, Michelle A., Hoagland, H. Clark, Call, Timothy G., Schroeder, Georgene S., Yoon, Soo‐Young, Li, Chin‐Yang, Gray, Leigh A., Margolin, S., Hook, C. Christopher

“…The anti‐fibrotic and cytokine modulatory properties of pirfenidone suggest its usefulness in the treatment of myelofibrosis with myeloid metaplasia (MMM). In…”
Get full text

Phase III Evaluation of Octreotide versus Chemotherapy with 5-Fluorouracil or 5-Fluorouracil Plus Leucovorin in Advanced Exocrine Pancreatic Cancer: A North Central Cancer Treatment Group Study by BURCH, Patrick A, BLOCK, Margaret, KUROSS, Steven A, SCHROEDER, Georgene, KUGLER, John W, SARGENT, Daniel J, BRAICH, Theodore A, MAILLIARD, James A, MICHALAK, John C, HATFIELD, Alan K, WRIGHT, Keith

“…There continues to be a need for new systemic approaches for the treatment of advanced pancreatic cancer. The purpose of this study was to compare the…”
Get full text

Short-term Quality-of-Life Outcomes Following Laparoscopic-Assisted Colectomy vs Open Colectomy for Colon Cancer: A Randomized Trial by Weeks, Jane C, Nelson, Heidi, Gelber, Shari, Sargent, Daniel, Schroeder, Georgene, for the Clinical Outcomes of Surgical Therapy (COST) Study Group

“…CONTEXT Laparoscopic-assisted colectomy (LAC) has emerged as the preferred minimally invasive surgical strategy for diseases of the colon. The safety and…”
Get full text

Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia by Mesa, Ruben A., Hanson, Curtis A., Rajkumar, S. Vincent, Schroeder, Georgene, Tefferi, Ayalew

“…Recent observations have underscored the biologic relevance of intratumoral angiogenesis and its potential impact on prognosis. Increased bone marrow…”
Get full text

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia by Mesa, Ruben A., Steensma, David P., Pardanani, Animesh, Li, Chin-Yang, Elliott, Michelle, Kaufmann, Scott H., Wiseman, Gregory, Gray, Leigh A., Schroeder, Georgene, Reeder, Terra, Zeldis, Jerome B., Tefferi, Ayalew

“…Single-agent thalidomide (THAL) at “conventional” doses (> 100 mg/d) has been evaluated in myelofibrosis with myeloid metaplasia (MMM) based on its…”
Get full text

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients by Tefferi, Ayalew, Mesa, Ruben A., Nagorney, David M., Schroeder, Georgene, Silverstein, Murray N.

“…In a 20-year period, 223 patients (median age, 64.8 years) with myelofibrosis with myeloid metaplasia (MMM) had therapeutic splenectomy at our institution…”
Get full text

Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia by Mesa, Ruben A., Hanson, Curtis A., Rajkumar, S. Vincent, Schroeder, Georgene, Tefferi, Ayalew

“…Recent observations have underscored the biologic relevance of intratumoral angiogenesis and its potential impact on prognosis. Increased bone marrow…”
Get full text

Characteristics of patients with vaginal rupture and evisceration by CROAK, Andrew J, GEBHART, John B, KLINGELE, Christopher J, SCHROEDER, Georgene, LEE, Raymond A, PODRATZ, Karl C

“…To characterize vaginal rupture and evisceration. We reviewed medical records (1970-2001) for use of the diagnostic terms "vaginal rupture," "vaginal…”
Get full text

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia by Tefferi, Ayalew, Mesa, Ruben A., Schroeder, Georgene, Hanson, Curtis A., Li, Chin‐Yang, Dewald, Gordon W.

“…The prognostic significance of bone marrow cytogenetic lesions in myelofibrosis with myeloid metaplasia (MMM) was investigated in a retrospective series of 165…”
Get full text

Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome by Steensma, David P., Dispenzieri, Angela, Moore, S. Breanndan, Schroeder, Georgene, Tefferi, Ayalew

“…Antithymocyte globulin (ATG) has recently been popularized as an effective treatment in myelodysplastic syndrome (MDS). We treated 8 anemic MDS patients…”
Get full text

A prospective, randomized crossover study comparing direct inspection by light microscopy versus projected images for teaching of hematopathology to medical students by Carlson, Aaron M., McPhail, Ellen D., Rodriguez, Vilmarie, Schroeder, Georgene, Wolanskyj, Alexandra P.

“…Instruction in hematopathology at Mayo Medical School has evolved from instructor‐guided direct inspection under the light microscope (laboratory method), to…”
Get full text

Durable responses to thalidomide-based drug therapy for myelofibrosis with myeloid metaplasia by Mesa, Ruben A, Elliott, Michelle A, Schroeder, Georgene, Tefferi, Ayalew

“…To present the results of a long-term analysis of 2 sequential phase 2 trials of thalidomide (alone or in combination) for palliation of myelofibrosis with…”
Get more information

Wound recurrence following conventional treatment of colorectal cancer. A rare but perhaps underestimated problem by Reilly, W T, Nelson, H, Schroeder, G, Wieand, H S, Bolton, J, O'Connell, M J

“…Reports of trocar and extraction site tumor recurrences following laparoscopic colectomy raise concern that such recurrences may be occurring more frequently…”
Get more information

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma by Pitot, H C, Wender, D B, O'Connell, M J, Schroeder, G, Goldberg, R M, Rubin, J, Mailliard, J A, Knost, J A, Ghosh, C, Kirschling, R J, Levitt, R, Windschitl, H E

“…To evaluate the objective tumor response rate and toxicities of patients with metastatic colorectal carcinoma treated with irinotecan hydrochloride (CPT-11). A…”
Get more information

Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocythemia by Mesa, Ruben A., Hanson, Curtis A., Li, Chin-Yang, Yoon, Soo-Young, Rajkumar, S. Vincent, Schroeder, Georgene, Tefferi, Ayalew

“…The lack of diagnostic certainty in some patients makes it difficult to distinguish between primary and secondary forms of thrombocytosis. To augment current…”
Get full text

Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis by Pardanani, Animesh, Witzig, Thomas E., Schroeder, Georgene, McElroy, Edwin A., Fonseca, Rafael, Dispenzieri, Angela, Lacy, Martha Q., Lust, John A., Kyle, Robert A., Greipp, Philip R., Gertz, Morie A., Rajkumar, S. Vincent

“…This study examined the prognostic value of circulating peripheral blood plasma cells (PBPCs) in patients with primary systemic amyloidosis (AL). A sensitive…”
Get full text

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia by Tefferi, Ayalew, Mesa, Ruben A., Gray, Leigh A., Steensma, David P., Camoriano, John K., Elliott, Michelle A., Pardanani, Animesh, Ansell, Stephen M., Call, Timothy G., Colon-Otero, Gerardo, Schroeder, Georgene, Hanson, Curtis A., Dewald, Gordon W., Kaufmann, Scott H.

“…In a phase 2 study, 23 patients with myelofibrosis with myeloid metaplasia were treated with imatinib mesylate at a constant dose of 400 mg/d. Treatment was…”
Get full text